BCR and chronic myelogenous leukemia, BCR-ABL1 positive: However, TKI resistance, which results mainly from BCR/ABL point mutation or gene amplification and also via BCR/ABL-independent mechanisms, is currently a major clinical concern in CML treatment [4].